95.74
4.62 (5.07%)
| Previous Close | 91.12 |
| Open | 93.75 |
| Volume | 563,219 |
| Avg. Volume (3M) | 639,485 |
| Market Cap | 5,658,186,240 |
| Price / Earnings (TTM) | 46.93 |
| Price / Earnings (Forward) | 28.90 |
| Price / Sales | 4.05 |
| Price / Book | 3.87 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 |
| Profit Margin | 8.81% |
| Operating Margin (TTM) | 11.83% |
| Diluted EPS (TTM) | 2.04 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 57.24% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | 225.16 M |
| Levered Free Cash Flow (TTM) | 172.75 M |
| Return on Assets (TTM) | 4.32% |
| Return on Equity (TTM) | 9.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Merit Medical Systems, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 1.63 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 109.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 112.00 (Canaccord Genuity, 16.98%) | Buy |
| Median | 108.00 (12.81%) | |
| Low | 103.00 (Barrington Research, 7.58%) | Buy |
| Average | 108.43 (13.26%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 95.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Jul 2025 | 108.00 (12.81%) | Buy | 95.74 |
| 20 May 2025 | 108.00 (12.81%) | Buy | 98.81 | |
| Piper Sandler | 23 May 2025 | 110.00 (14.89%) | Buy | 95.38 |
| 23 Apr 2025 | 112.00 (16.98%) | Buy | 93.76 | |
| Canaccord Genuity | 21 May 2025 | 112.00 (16.98%) | Buy | 96.49 |
| 25 Apr 2025 | 108.00 (12.81%) | Buy | 94.61 | |
| Wells Fargo | 21 May 2025 | 108.00 (12.81%) | Buy | 96.49 |
| Baird | 25 Apr 2025 | 110.00 (14.89%) | Buy | 94.61 |
| Barrington Research | 25 Apr 2025 | 103.00 (7.58%) | Buy | 94.61 |
| Raymond James | 25 Apr 2025 | 108.00 (12.81%) | Buy | 94.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jul 2025 | Announcement | Merit Medical Names Martha Aronson as New President and Chief Executive Officer |
| 03 Jul 2025 | Announcement | Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 |
| 20 May 2025 | Announcement | Merit Medical Acquires Biolife Delaware, L.L.C. |
| 06 May 2025 | Announcement | Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis |
| 05 May 2025 | Announcement | Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial |
| 24 Apr 2025 | Announcement | Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |